The Globe and Mail reports in its Tuesday, Nov. 4, edition that Canaccord Genuity analyst Yuri Lynk has reaffirmed his "buy" recommendation for Atkinsrealis Group. The Globe's David Leeder writes in the Eye On Equities column that Mr. Lynk gave his share target a $7 boost to $125. Analysts on average target the shares at $113. Mr. Lynk says in a note: "In our view, Atkinsrealis is well-positioned in favourable end-markets that are experiencing consistent growth on the back of secular trends such as electrification, decarbonization, and infrastructure renewal and expansion. Management is executing well and largely delivering on its targets. Recent momentum in the nuclear segment is particularly important for the stock because it's the part of the business we ascribe the highest valuation to, based on where comparables trade. Our 'buy' rating is predicated on Atkinsrealis's unique nuclear business backstopped by proprietary technology (CANDU); its balance sheet, which is the strongest in the group with over $250-million of net cash; and its discounted valuation." The Globe reported on April 11 and July 31 that Mr. Lynk continued to rate Atkinsrealis "buy." The shares could then be had for $65.33 and $98.11.